Use of topiramate in childhood generalized seizure disorders

Journal of Child Neurology

Volumn 15, Issue SUPPL. 1, 2000, Pages

  Wheless, J W ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; FRUCTOSE; LAMOTRIGINE; PHENYTOIN; PLACEBO; TOPIRAMATE; VALPROIC ACID;

ABSENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; BENIGN CHILDHOOD EPILEPSY; CATALEPSY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG EFFICACY; EPILEPSY; EPILEPTIC STATE; FOCAL EPILEPSY; GRAND MAL SEIZURE; HUMAN; INFANTILE SPASM; LENNOX GASTAUT SYNDROME; MALE; MULTICENTER STUDY; MYOCLONUS SEIZURE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; SIDE EFFECT; SYNDROME; TONIC CLONIC SEIZURE;

EID: 0034469917     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/0883073800015001s03     Document Type: Article

References (83)

1. Social issues in epilepsy
2. Injuries and death as a consequence of seizures in people with epilepsy
3. Patient's experiences of injury as a result of epilepsy
4. Injury and death as a result of seizures
5. Quality of life of people with epilepsy: A European study
6. Community-based study of mortality in children with epilepsy
7. The incidence of epilepsy and unprovoked seizures in Rochester, Minnesota, 1935-1984
8. Anticonvulsant O-alkyl sulfamates. 2, 3:4, 5-bis. O- (1-methylethylidene-)-beta-D-fructopyranose sulfamate and related compounds
9. Topiramate: Pre-clinical evaluation of a structurally novel anticonvulsant
10. An overview of the pre-clinical aspects of topiramate: Pharmacology, pharmacokinetics, and mechanism of action
11. Selective effects of topiramate on sustained repetitive firing and spontaneous bursting in cultured hippocampal neurons
12. Effects of topiramate on sustained repetitive firing and low Mg2+-induced seizure discharges in cultured hippocampal neurons
13. Effects of topiramate on sodium-dependent action-potential firing by mouse spinal cord neurons in cell culture
14. The novel anticonvulsant topiramate enhances GABA-mediated chloride flux
15. The investigational anticonvulsant topiramate potentiates GABA-evoked currents in mouse cortical neurons
16. Topiramate increases cerebral GABA in healthy humans
17. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism
18. Topiramate selectively blocks kainate currents in cultured hippocampal neurons
19. Cellular actions of topiramate: Blockade of kainate-evoked inward currents in cultured hippocampal neurons
20. Modulation of high voltage-activated calcium channels in dentate granule cells by topiramate
21. Topiramate as an inhibitor of carbonic anhydrous isoenzymes
22. Topiramate in the catastrophic epilepsies of childhood
23. Topiramate placebo-controlled dose ranging trial in refractory partial epilepsy using 600-, 800-, and 1000-mg daily dosages
24. Topiramate placebo-controlled dose ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages
25. Double-blind placebo controlled trial of topiramate as add-on therapy in patients with refractory partial seizures
26. Topiramate in medically intractable partial epilepsies: Double-blind placebo controlled randomized parallel group trial
27. Efficacy of topiramate as adjunctive therapy in refractory partial seizures: United States trial experience
28. Clinical efficacy of topiramate as add-on therapy in refractory partial epilepsy: The European Experience
29. A double-blind randomized trial of topiramate as adjunctive therapy for partial onset seizures in children
30. A study of topiramate pharmacokinetics and tolerability in children with epilepsy
31. Topiramate: A review of its pharmacodynamics and pharmacokinetic properties and clinical efficacy in the management of epilepsy
32. Topiramate YOL study group: Topiramate in the long-term management of refractory epilepsy
33. Preliminary open-label experience with topiramate in primary generalized seizures
34. Topiramate for drug-resistant epilepsies
35. Clinical experience with topiramate in children with intractable epilepsy
36. Topiramate: A new anti-epileptic drug with success in children
37. Topiramate in drug resistant partial and generalized epilepsies
38. Broad-spectrum efficacy of topiramate in children
39. Topiramate for drug resistant epilepsies in children
40. PADS Investigators: Post-marketing analysis of topiramate in the treatment of primary generalized epilepsy
41. Post-marketing multicenter open study of topiramate in children
42. PADS Investigators: Long-term post-marketing analysis of lamotrigine and topiramate in the treatment of generalized epilepsy
43. Topiramate for intractable childhood epilepsy
44. A randomized placebo controlled study of topiramate in primary generalized tonic-clonic seizures
45. Topiramate: A broad-spectrum agent in patients with juvenile myoclonic epilepsy
46. Topiramate YTC-E study group: A double-blind trial of topiramate in patients with generalized tonic-clonic seizures of non-focal origin
47. Topiramate in juvenile myoclonic epilepsy: Observations from randomized controlled trials in primary generalized tonic-clonic seizures
48. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures
49. Non-focal generalized tonic-clonic seizures: Response during long-term topiramate treatment
50. Inhibition by topiramate of seizures in spontaneously epileptic rats and DBA/2 mice
51. Topiramate monotherapy for childhood absence seizures: Results from an open-label pilot study
52. Topiramate pharmacokinetics in infants
53. Topiramate reduces neuronal injury after experimental status epilepticus
54. Topiramate blocks acute and chronic epileptogenesis in a rat model of perinatal hypoxic encephalopathy
55. Efficacy and adverse effects of established and new antiepileptic drugs
56. Valproate monotherapy in the management of generalized and partial seizures
57. Efficacy and safety of valproic acid versus phenytoin as solo therapy for newly diagnosed primary generalized tonic-clonic seizures
58. Comparison of valproic acid and phenytoin in newly diagnosed tonic-clonic seizures
59. Monotherapy with valproate in primary generalized epilepsies
60. Pancreatitis associated with valproic acid therapy
61. Pancreatitis associated with valproic acid therapy
62. Valproate associated pancreatitis
63. Valproic acid hepatic fatalities: A retrospective review
64. Fatal liver failure in 16 children with valproate therapy
65. Valproic acid hepatic fatalities III-U.S. experience since 1986
66. Valproic acid hepatic fatalities II-U.S. experience since 1984
67. Valproic toxicity: Risk screening strategies
68. Antiepileptic drugs as a cause of worsening seizures
69. Double-blind, placebo-controlled, cross-over study of vigabatrin in drug resistant epilepsy of the adult
70. Double-blind study of vigabatrin in the treatment of drug resistant epilepsy
71. Gabapentin in generalized seizures
72. Gabapentin in naive childhood absence epilepsy: Results from two double-blind, placebo-controlled, multi-center studies
73. Lamictal (lamotrigine) monotherapy for typical absence seizures in children
74. Double-blind, placebo-controlled, cross-over study of lamotrigine in treatment-resistant generalized epilepsy
75. Dramatic effect of lamotrigine in young adults suffering from intractable absences and generalized tonic-clonic seizures since childhood
76. Lamotrigine for the treatment of epilepsy in childhood
77. Lamotrigine associated anti-convulsant hypersensitivity syndrome
78. Safety of long-term lamotrigine in epilepsy
79. Practice advisory: The use of felbamate in the treatment of patients with intractable epilepsy
80. Felbamate-associated fatal acute hepatic necrosis
81. Aplastic anemia in 9 patients receiving felbamate for complex partial seizures
82. Topiramate as add-on therapy: Pooled analysis of randomized controlled trials in adults
83. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy